BACKGROUND: Molecular methods have become essential in the diagnosis of visceral leishmaniasis (VL) in patients who have AIDS. The present study aimed at (1) identifying relapse risk factors for VL and (2) assessing the value of long-range routine polymerase chain reaction (PCR) monitoring in such patients, (3) with a view to proposing decision-making elements for discontinuing specific secondary prophylaxis. METHODS: A cohort of 27 HIV-positive patients was prospectively followed up during a period of 5 months to 9 years (median = 51 months) after a first episode of VL. The clinical and biologic follow-up protocol included routine Leishmania detection using peripheral blood and a previously validated PCR method. Quantitative and qualitative variables were statistically analyzed. RESULTS: Sixteen patients relapsed, for a total of 38 relapses. CD4 counts <100 cells/microL and absence of highly active antiretroviral therapy at primary diagnosis and CD4 counts <100 cells/microL during follow-up were the major predictive factors for relapse. No relapse occurred when CD4 counts were >200 cells/microL. The Leishmania PCR assay was positive in all clinical relapses, and its negative predictive value was 100%. CONCLUSIONS: The PCR assay used here proved extremely useful for routine follow-up of VL in patients who had AIDS. Considering CD4 cell counts and Leishmania PCR assays, these results allow defining proposals for discontinuing secondary prophylaxis, and thus optimizing the clinical care of VL in these patients.
BACKGROUND: Molecular methods have become essential in the diagnosis of visceral leishmaniasis (VL) in patients who have AIDS. The present study aimed at (1) identifying relapse risk factors for VL and (2) assessing the value of long-range routine polymerase chain reaction (PCR) monitoring in such patients, (3) with a view to proposing decision-making elements for discontinuing specific secondary prophylaxis. METHODS: A cohort of 27 HIV-positive patients was prospectively followed up during a period of 5 months to 9 years (median = 51 months) after a first episode of VL. The clinical and biologic follow-up protocol included routine Leishmania detection using peripheral blood and a previously validated PCR method. Quantitative and qualitative variables were statistically analyzed. RESULTS: Sixteen patients relapsed, for a total of 38 relapses. CD4 counts <100 cells/microL and absence of highly active antiretroviral therapy at primary diagnosis and CD4 counts <100 cells/microL during follow-up were the major predictive factors for relapse. No relapse occurred when CD4 counts were >200 cells/microL. The Leishmania PCR assay was positive in all clinical relapses, and its negative predictive value was 100%. CONCLUSIONS: The PCR assay used here proved extremely useful for routine follow-up of VL in patients who had AIDS. Considering CD4 cell counts and Leishmania PCR assays, these results allow defining proposals for discontinuing secondary prophylaxis, and thus optimizing the clinical care of VL in these patients.
Authors: Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo Journal: Drug Dev Res Date: 2011-09 Impact factor: 4.360
Authors: Gabriel Reis Ferreira; José Carlos Castelo Branco Ribeiro; Antônio Meneses Filho; Teresinha de Jesus Cardoso Farias Pereira; Daniela Moura Parente; Humberto Feitosa Pereira; Jailthon Carlos da Silva; Danielle Alves Zacarias; Letiano Vieira da Silva; Symonara Karina Medeiros Faustino; Walfrido Salmito Almeida Neto; Dorcas Lamounier Costa; Ivete Lopes de Mendonça; Carlos Henrique Nery Costa Journal: Am J Trop Med Hyg Date: 2018-01 Impact factor: 2.345
Authors: Eline Eberhardt; Annelies Mondelaers; Sarah Hendrickx; Magali Van den Kerkhof; Louis Maes; Guy Caljon Journal: Parasitol Res Date: 2016-07-13 Impact factor: 2.289
Authors: Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa Journal: Am J Trop Med Hyg Date: 2014-03-10 Impact factor: 2.345
Authors: Israel Molina; Roser Fisa; Cristina Riera; Vicenç Falcó; Aleix Elizalde; Fernando Salvador; Manuel Crespo; Adrian Curran; Paulo López-Chejade; Silvia Tebar; Santiago Pérez-Hoyos; Esteban Ribera; Albert Pahissa Journal: Am J Trop Med Hyg Date: 2013-04-29 Impact factor: 2.345